| Yang CM |
------>authors3_c=??? ------>paper_class1=1 ------>Impact_Factor=None ------>paper_class3=1 ------>paper_class2=1 ------>vol=16 ------>confirm_bywho=henry11111 ------>insert_bywho=cyang ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=30 ------>paper_class2Letter=None ------>page2=10 ------>medlineContent= ------>unit=J0800 ------>insert_date=20091010 ------>iam=1 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c=??? ------>score=33 ------>journal_name=???? ------>paper_name=?ICH???????????????????????? ------>confirm_date=20091010 ------>tch_id=087013 ------>pmid=19922536 ------>page1=4 ------>fullAbstract=The ICH E14 guidance on how to clinically assess a new drug~s liability to prolong the QT interval was adopted in May 2005. A centre-piece of the guidance was the establishment of one single trial, the ~thorough QT/QTcstudy~, intended to confidently identify drugs that may cause QT prolongation. Initially perceived as a great challenge, this study has rapidly become a standard component of all clinical development programs for new molecular entities. The study is normally conducted in healthy volunteers, includes both a positive and a negative (placebo) control and is stringently powered to exclude an effect on the QTc interval exceeding 10 ms. The E14 guidance was intentionally not very prescriptive and allowed sponsors and service providers to explore new methodologies. This has allowed for a rapid development of new methods during the first years after the guidance~s implementation, such as computer-assisted algorithms for QT measurements. Regulators have worked in close collaboration with pharmaceutical industry to set standards for the design and conduct of the ~thorough QT/QTc study~, which therefore has evolved as a key component of cardiac safety assessment of new drugs. This paper summarizes the requirements on the ~thorough QT/QTc study~ with emphasis on the standard that has evolved based on interactions between regulators and sponsors and the experience from a large number of completed studies. ------>tmu_sno=None ------>sno=22462 ------>authors2=Lee YC ------>authors3=Li SC ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Yang CM ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=??? ------>publish_area=0 ------>updateTitle=The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. ------>language=1 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=3 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2009 ------>submit_flag=None ------>publish_month=9 |